Ruxolitinib
Atypical Ductal Hyperplasia
Julie NangiaSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Atypical Ductal Hyperplasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin Alliance for Clinical Trials in Oncology | Phase 3 | B |
Lipitor National Cancer Institute (NCI) | Phase 1 | CC |
Bexarotene National Cancer Institute (NCI) | Phase 1 | CC |
som230 NYU Langone Health | Phase 1 | CC |
Pasireotide NYU Langone Health | Phase 1 | CC |
Same molecule, other indications
Ruxolitinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →